• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube have similar outcomes

byRicha SharmaandRavi Shah, MD MBA
February 16, 2020
in Oncology, Pulmonology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with malignant pleural effusions, this randomized control trial of thoracoscopic talc poudrage versus talc slurry administered via chest tube found no significant differences in outcomes at 180 days. 

2. Differences may be present between the treatment groups that were not detected by the study.

Evidence Rating Level: 2 (Good)

Study Rundown: The number of cancer cases reported globally are on the rise. A common complication of cancer are malignant pleural effusions, which, if not treated promptly, can lead to worsening dyspnea and reduced quality of life. Talc delivery to the pleural space has been shown to induce pleurodesis. This study compared thoracoscopic talc poudrage with talc slurry delivered via chest tube to compare the induction of pleurodesis. In the primary outcome of pleurodesis failure, no significant difference between the two treatment procedures were found.

This study is limited by its lack of generalizability to all patients with a malignant pleural effusion.  Thoracoscopy under moderate sedation, could only be provided to those who are able to tolerate and undergo the procedure.  Moreover, the physicians were not blinded to the randomization procedure at time of the follow-up, which may have led to a form of bias regarding follow-up interventions.

Click to read the study in JAMA

Relevant Reading: Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions: the ASAP trial.

RELATED REPORTS

Pleural effusions associated with worse survival in non-small-cell lung cancer

In-Depth [randomized controlled trial]: In this study, a total of 330 participants were enrolled from 17 hospitals in the United Kingdom and randomized into one of the two treatment groups. The enrollment period lasted from August 2012 to April 2018 and the follow up phase ended in October 2018. In order to be eligible, patients had to be above 18 years of age, with an estimated survival of over 3 months and a diagnosis of malignant pleural effusion, diagnosis of cancer with an unexplained effusion or visible pleural changes on radiology consistent with malignancy. Patients also had to be able to tolerate thoracoscopy under moderate sedation.  Patients were excluded if pregnant, lactating, known contraindication to pleurodesis or any study intervention. There was not significant difference between the groups in pleurodesis failure rate (22% vs 24% p-0.74).  Overall, no statistically significant differences in the prespecified secondary outcomes at 180 days including mortality, dyspnea, and health-related quality of life.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: malignant effusionpleural effusionpleurodesistalc
Previous Post

Fibrinogen concentrate noninferior to cryoprecipitate after cardiac surgery in patients with excessive bleeding and hypofibrinogenemia

Next Post

Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women

RelatedReports

Afatinib shows increased progression-free survival in non-small-cell lung cancer
Oncology

Pleural effusions associated with worse survival in non-small-cell lung cancer

February 21, 2014
Next Post
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women

Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women

Parents with poor sleep quality report sleep problems in kids

Short and late sleep associated with adiposity in children

#VisualAbstract: Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia

#VisualAbstract: Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Patients with early pregnancy loss less likely to receive active management in the emergency department
  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options